Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders

Evome Medical Technologies Inc. (the “

Company

” or “

Evome

”) (TSXV: EVMT) today announced ‎the results from its annual general and special meeting of shareholders held on November 8, 2024 (the ‎‎“

Meeting

”) in Shirley, New York. The total number of shares represented in person or by proxy at the Meeting was ‎‎‎18,991,213‎, representing 31.2% of the total issued and outstanding voting shares of the Company.‎

All matters placed before shareholders were approved including the approval of an amended and restated 2023 Equity Incentive Plan (the “A&R 2023 Equity Incentive Plan”). The A&R 2023 Equity Incentive Plan replaces the 2023 Equity Incentive Plan which became effective and was approved by shareholders on August 11, 2023, reserving. The only difference between the A&R 2023 Equity Incentive Plan and the 2023 ‎Equity Incentive Plan is the increase of the maximum number of common ‎shares that may be available and reserved for ‎issuance pursuant to awards, at any time, which has been increased from 11,284,618 common shares to 11,961,275. The A&R 2023 Equity Incentive Plan is described in detail in the management information circular ‎dated October 4, 2024 filed under the Company’s SEDAR+ profile on October 18, 2024, and a copy has been filed under the Company’s SEDAR+ profile.‎

About Evome

Evome Medical Technologies Inc. (TSXV: EVMT) specializes in human performance and rehabilitative solutions achieved through strategic acquisitions and leveraging the intellectual properties of specialized companies under its wholly-owned subsidiaries. Evome’s goal is to create a large, broad-based medical device company with global reach. For more information visit www.evomemedical.com.

Biodex® is a leader in innovative rehabilitation solutions, recognized for its advanced product line serving orthopedic, sports medicine and neurorehabilitation needs. Renowned for its precision and durability, Biodex® offers advanced equipment such as balance and mobility systems, isokinetic testing devices and comprehensive upper extremity rehabilitation tools. With a presence in over 70 countries and partnerships with 52 distributors, Biodex® continues to drive advancements in patient care through a strong commitment to research, education and technology integration.

For Additional Information:

Mike Seckler ‎Chief Executive [e-mail]‎

For Media and Investor Relations:

irlabsAlyssa BarryPrincipal and Co-Founder1 [phone]

Additional Information

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ‎policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ‎release.‎

There can be no assurance that any acquisitions will be completed or the sale price or timing of any acquisition. Completion of any transaction will be ‎subject to, amongst other things, negotiation and execution of definitive agreements, and applicable ‎director, shareholder and regulatory approvals.‎